Ivonescimab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: ivonescimab in combination with chemotherapy for the first-line treatment of advanced... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Reliable signal

Also in development:Metastatic Colorectal Cancer · Phase 3 · investigational in the USBiliary Tract Cancer · Phase 3 · investigational in the US · under NMPA review

Also approved (3)
CN
  • ivonescimab in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC)akesobio.com
  • monotherapy for the first-line treatment of PD-L1-positive (TPS ≥ 1%) non-small cell lung cancer (NSCLC)akesobio.com
  • ivonescimab combined with platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI)
    akesobio.com
Product first approved 2024

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Biliary Tract Cancer
Metastatic Colorectal Cancer
NCT07228832 · Summit Therapeutics
2025-11-18 – 2029-11-30 · Metastatic Colorectal Cancer (CRC)
What this study did
NCT06951503 · Akeso
2025-05-27 – 2029-01-07 · Colorectal Adenocarcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06767514 · Summit Therapeutics
2025-02-27 – 2029-06 · Non-Small Cell Lung Cancer
What this study did
NCT05840016 · Akeso
2023-08-17 – 2026-12-31 · Advanced Squamous Non Small Cell Lung Cancer
What this study did
NCT06396065 · Summit Therapeutics
2023-05-04 – 2026-12-31 · Non-Squamous Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07264075 · Groupe Oncologie Radiotherapie Tete et Cou
2026-05-05 – 2030-05 · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
What this study did
NCT06767527 · Akeso
2025-02-07 – 2028-12 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT06953999 · Akeso
2025-06-11 – 2028-05-14 · Pancreatic Cancer
What this study did
NCT06601335 · Akeso
2024-10-30 – 2027-10 · Head and Neck Squamous Cell Carcinoma
What this study did
Phase 2/3 (2)
Biliary Tract Cancer
NCT07765433 · ECOG-ACRIN Cancer Research Group
2027-01-11 – 2029-12-31 · Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma, Metastatic Biliary Tract Adenocarcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Adenocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Adenocarcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
Other / comorbidity
NCT07815665 · Summit Therapeutics
2026-09-10 – 2030-12-31 · Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
What this study did
Phase 2 (118)
Biliary Tract Cancer
NCT07854600 · Haitao Zhao, MD
2026-10 – 2029-12 · Biliary Tract Cancer (BTC)
What this study did
NCT06529718 · UNICANCER
2025-10-09 – 2029-01-30 · Biliary Tract Cancer
What this study did
NCT06993025 · Tianjin Medical University Cancer Institute and Hospital
2025-05-25 – 2027-04-25 · Biliary Tract Cancer
What this study did
Metastatic Colorectal Cancer
NCT07359456 · UNICANCER
2026-08-31 – 2033-08 · Metastatic Colorectal Cancer
What this study did
NCT06959550 · M.D. Anderson Cancer Center
2025-07-28 – 2030-07-01 · Metastatic Colorectal Cancer
What this study did
NCT07021950 · Sun Yat-sen University
2025-08-10 – 2028-12-31 · Colorectal Cancer, Ivonescimab
What this study did
NCT05382442 · Akeso
2022-06-27 – 2028-08-12 · Metastatic Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07234877 · European Organisation for Research and Treatment of Cancer - EORTC
2026-11 – 2032-04 · Non Small Cell Lung Cancer
What this study did
NCT06951646 · Second Xiangya Hospital of Central South University
2026-03-10 – 2030-06-01 · Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
What this study did
NCT07941583 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-12-01 – 2030-06-01 · EGFR-Mutant NSCLC
What this study did
NCT07742956 · Shanghai Allink Biotherapeutics Co., Ltd.
2026-08-20 – 2029-12-31 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07393555 · SWOG Cancer Research Network
2026-09-22 – 2029-11 · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
NCT07936578 · Guizhou Medical University
2026-10-30 – 2029-10-30 · Concurrent Chemoradiotherapy, Immunotherapy, Lung Cancer (NSCLC)
What this study did
The IVO-LUNG Studynot yet recruiting
NCT07204548 · Sun Yat-sen University
2025-10 – 2029-10 · Non Small Cell Lung Cancer (Stage III)
What this study did
NCT07158489 · Swiss Cancer Institute
2026-08-21 – 2029-07-31 · NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07669779 · Akeso
2026-07-10 – 2029-05-30 · Advanced Non Small Cell Lung Cancer (NSCLC)
What this study did
NCT07412262 · Guangdong Association of Clinical Trials
2026-08-28 – 2029-03-31 · Non-Small Cell Lung Cancer
What this study did
NCT07405190 · Massachusetts General Hospital
2026-05-01 – 2029-03-01 · Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell), Lung Cancer - Non Small Cell, Lung Cancer Non Small Cell, Genomic Alterations
What this study did
NCT07669051 · Shandong Cancer Hospital and Institute
2026-01-01 – 2029-01-01 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07489703 · Sun Yat-sen University
2026-04-30 – 2028-12-31 · Non-Small Cell Lung Cancer
What this study did
NCT07603791 · Shanghai Allink Biotherapeutics Co., Ltd.
2026-06-30 – 2028-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT07241819 · Peking University Cancer Hospital & Institute
2025-11-30 – 2028-11-30 · II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer, Perioperative
What this study did
NCT07630077 · Sun Yat-sen University
2026-07-01 – 2028-07-01 · Non Small Cell Lung Cancer
What this study did
NCT07009925 · Jiangsu Cancer Institute & Hospital
2025-06 – 2028-05 · Squamous Cell Lung Cancer
What this study did
NCT07472478 · Guangdong Provincial People's Hospital
2026-03-20 – 2028-03-31 · Lung Cancer (NSCLC), KRAS G12C Lung Cancer
What this study did
NCT06769295 · Sichuan University
2025-02-01 – 2027-12-31 · Lung Cancer, Non-Small Cell
What this study did
NCT05247684 · Akeso
2022-02-20 – 2027-12-31 · Resectable Non-small Cell Lung Cancer
What this study did
NCT07086326 · Yang Fan, MD
2025-07-31 – 2027-12-30 · NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112, Bispecific Antibody
What this study did
NCT04736823 · Akeso
2021-02-01 – 2026-12 · NSCLC
What this study did
NCT06391008 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2024-04-30 – 2025-06-30 · Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07743632 · University of Kansas Medical Center
2026-09 – 2033-12 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT07244978 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-06-03 – 2032-12-31 · Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
What this study did
NCT07753824 · M.D. Anderson Cancer Center
2027-01-16 – 2032-11-28 · Phase II, Ivonescimab, Intraperitoneal, Paclitaxel, High Grade Metastatic, Appendiceal Adenocarcinoma
What this study did
NCT07017673 · Cedars-Sinai Medical Center
2025-07-25 – 2032-11 · TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
What this study did
NCT06977542 · Fudan University
2025-06 – 2032-01 · TNBC, Triple Negative Breast Cancer
What this study did
NCT06760520 · The First Affiliated Hospital of Zhengzhou University
2025-01-20 – 2031-12-20 · Locally Advanced Rectal Cancer
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07565389 · National University Hospital, Singapore
2026-05 – 2031-05 · Nasopharyngeal Carcinoma (NPC)
What this study did
NCT07094685 · University of Michigan Rogel Cancer Center
2025-11-18 – 2030-11-01 · Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma
What this study did
NCT06567314 · M.D. Anderson Cancer Center
2024-12-02 – 2030-09-01 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT07130240 · Obstetrics & Gynecology Hospital of Fudan University
2025-08-15 – 2030-08-31 · Cervical Cancers
What this study did
NCT07743138 · M.D. Anderson Cancer Center
2027-02-07 – 2030-05-01 · Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
What this study did
NCT06814067 · Fudan University
2025-02-10 – 2030-03-01 · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
What this study did
NCT06940518 · M.D. Anderson Cancer Center
2025-07-02 – 2030-01-19 · Ivonescimab, Clear Cell Renal Carcinoma
What this study did
NCT07057791 · PrECOG, LLC.
2026-03-30 – 2030-01 · Extensive Stage Lung Small Cell Cancer
What this study did
NCT07877194 · Summit Therapeutics
2026-10-19 – 2029-12-12 · Renal Cell Carcinoma, Clear Cell
What this study did
Phase 1/2 (33)
Biliary Tract Cancer
NCT06938321 · Akeso
2025-04-30 – 2027-12 · Biliary Tract Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07623356 · Akeso
2026-07-07 – 2030-07-03 · Non-Small Cell Lung Cancer
What this study did
NCT07339839 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-03-01 – 2029-09-30 · NSCLC Stage IV, KRAS G12C
What this study did
NCT07397338 · Revolution Medicines, Inc.
2026-01-30 – 2029-05 · Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
What this study did
NCT07594522 · Memorial Sloan Kettering Cancer Center
2026-05-12 – 2028-05-12 · Non-Small Cell Lung Cancer
What this study did
NCT07535463 · Memorial Sloan Kettering Cancer Center
2026-04-10 – 2028-04 · Non-Small Cell Lung Cancer
What this study did
NCT07535437 · Memorial Sloan Kettering Cancer Center
2026-04-09 – 2028-04 · Non-Small Cell Lung Cancer
What this study did
NCT07590531 · Multitude Therapeutics Inc.
2026-06-29 – 2027-12-31 · Advanced Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT07208773 · MediLink Therapeutics (Suzhou) Co., Ltd.
2025-10-29 – 2027-12 · Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
What this study did
NCT06196814 · Hunan Province Tumor Hospital
2024-10-01 – 2027-02-01 · Efficacy
What this study did
NCT05904379 · Akeso
2023-07-13 – 2027-01-31 · Advanced Non-small-cell Lung Cancer
What this study did
NCT05636267 · Akeso
2023-02-10 – 2025-04-15 · NSCLC
What this study did
Other / comorbidity
NCT07560124 · Akeso
2026-06-06 – 2030-09-14 · Breast Cancer
What this study did
NCT06672575 · M.D. Anderson Cancer Center
2025-01-30 – 2030-01-31 · Glioblastoma
What this study did
NCT07602855 · GlaxoSmithKline
2026-09-09 – 2029-12-24 · Neoplasms, Lung
What this study did
NCT06957561 · Sun Yat-sen University
2025-04-30 – 2029-05-01 · Bladder Cancer, Muscle-invasive Bladder Cancer
What this study did
NCT06877650 · Shanghai JMT-Bio Inc.
2025-04-11 – 2029-03-30 · Advanced Malignant Tumors
What this study did
NCT07885319 · Ruijin Hospital
2026-11-01 – 2028-11-30 · Malignant Pleural Mesothelioma, Advanced
What this study did
NCT06530251 · Akeso
2024-09-24 – 2028-09 · Hepatocellular Carcinoma
What this study did
NCT07357220 · Akeso
2026-03-02 – 2028-02-28 · Colorectal Cancer With Hepatic Metastases
What this study did
NCT06844422 · Shandong Cancer Hospital and Institute
2025-02-08 – 2028-02-18 · Pancreatic Cancer
What this study did
NCT07385001 · Tang-Du Hospital
2026-01-28 – 2028-01-28 · Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
What this study did
NCT06646055 · Akeso
2025-01-21 – 2027-12-30 · Metastatic Pancreatic Ductal Adenocarcinoma
What this study did
NCT06472895 · Peking University Cancer Hospital & Institute
2024-07-20 – 2027-12-20 · Renal Cell Carcinoma
What this study did
NCT05229497 · Akeso
2022-05-04 – 2027-06-30 · Advanced Malignant Tumors
What this study did
NCT05689853 · Akeso
2023-04-14 – 2027-06 · Solid Tumor, Adult
What this study did
NCT05951608 · Akeso
2023-10-16 – 2026-08-15 · Advanced Solid Tumors
What this study did
NCT05846867 · Akeso
2023-05-08 – 2026-08-11 · Colorectal Cancer
What this study did
NCT06809517 · Guangzhou Medical University
2025-03-18 – 2026-05-01 · Leptomeningeal Metastasis, Intrathecal Drug Delivery
What this study did
NCT05214482 · Akeso
2022-01-22 – 2025-12-31 · Advanced Malignant Tumors
What this study did
NCT04597541 · Akeso
2020-10-21 – 2024-07-15 · Solid Tumor, Adult
What this study did
NCT04999605 · Akeso
2021-06-24 – 2022-06-10 · Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer, Ovarian Cancer
What this study did
Phase 1 (15)
Metastatic Colorectal Cancer
NCT07363408 · City of Hope Medical Center
2026-12-01 – 2027-07-21 · Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
What this study did
Non-Small Cell Lung Cancer
NCT07899086 · Hansoh BioMedical R&D Company
2026-11-10 – 2030-06-30 · Non-Small Cell Lung Cancer
What this study did
NCT07619339 · Memorial Sloan Kettering Cancer Center
2026-05-27 – 2029-05 · Non-Small Cell Lung Cancer
What this study did
NCT06868732 · Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2025-04-02 – 2028-12-30 · Advanced Non-small Cell Lung Cancer
What this study did
NCT07614646 · Everest Medicines (Beijing) Co., Ltd.
2026-11 – 2028-07 · Squamous Non-Small Cell Lung Cancer sqNSCLC
What this study did
Other / comorbidity
NCT05536141 · Arcus Biosciences, Inc.
2022-10-26 – 2029-03 · Clear Cell Renal Cell Carcinoma, Solid Tumors
What this study did
NCT06424626 · Peking University Cancer Hospital & Institute
2024-05-28 – 2028-12-31 · Melanoma, Mucosal Melanoma, Metastatic Melanoma
What this study did
NCT06929663 · Akeso
2025-07-02 – 2028-12-30 · Advanced Solid Tumors
What this study did
NCT07885306 · Ruijin Hospital
2025-03-12 – 2028-11-30 · Malignant Pleural Mesothelioma, Advanced
What this study did
NCT06913218 · Akeso
2025-07-22 – 2028-11-06 · Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
What this study did
NCT06990620 · Fudan University
2025-06 – 2027-12 · Hepatocellular Carcinoma (HCC)
What this study did
NCT07650825 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-08-01 – 2027-01-31 · Advanced Solid Tumors
What this study did
NCT07340476 · Akeso
2025-12-11 – 2026-07-30 · Healthy Male Subjects
What this study did
NCT04047290 · Akesobio Australia Pty Ltd
2019-09-20 – 2024-02-27 · Neoplasms Malignant
What this study did
NCT05116007 · Akeso
2021-03-29 – 2023-12-04 · SCLC, Extensive Stage
What this study did
Phase 4 (1)
Other / comorbidity
NCT06930573 · The First Affiliated Hospital of Zhengzhou University
2024-12-04 – 2027-12-24 · HCC
What this study did
Early phase / not applicable (2)
Non-Small Cell Lung Cancer
NCT06766591 · Jiangsu Province Nanjing Brain Hospital
2025-01-01 – 2025-10-31 · NSCLC, Chemotherapy, Leptomeningeal Metastases, EGFR-TKI, AK112
What this study did
Other / comorbidity
NCT06936488 · Huai'an First People's Hospital
2025-03-01 – 2026-12-31 · MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1/2 (1)
Other / comorbidity
NCT07857135 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-10-03 – 2029-08-03 · Advanced/Metastatic Solid Tumors
What this study did

Competitive landscape

Other PD-1 + VEGFA drugs

JS207. Compare all 2 PD-1 + VEGFA drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ivonescimab: this drugPhase 3Multispecific antibodyPD-1 + VEGFAReliable signal
NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized
NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
Iparomlimab And TuvonralimabPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
Precemtabart TocentecanPhase 1/2Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 68 furthest-along competitors are listed; 542 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(133 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ivonescimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (12)
December 2026 (12)
Phase 1/2Solid Tumor, AdultRecruiting
Est. primary completion 2026-12 · NCT05689853 · CT.gov ↗
What to watch
Phase 3Triple-Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2026-12 · NCT06767527 · CT.gov ↗
What to watch
Phase 2Stomach Cancer Stage IV, Esophagus Cancer, Stomach CancerRecruiting
Est. primary completion 2026-12-01 · NCT07070466 · CT.gov ↗
What to watch
Phase 2Relapsed or Metastatic Thymic Cancer, First-line TreatmentNot yet recruiting
Est. primary completion 2026-12-20 · NCT06750952 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06646055 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-30 · NCT07086326 · CT.gov ↗
What to watch
Phase 2Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05227664 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant TumorsActive not recruiting
Est. primary completion 2026-12-31 · NCT05229497 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06769295 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06769971 · CT.gov ↗
What to watch
Phase 2SCLCNot yet recruiting
Est. primary completion 2026-12-31 · NCT06820762 · CT.gov ↗
What to watch
Phase 2Triple-Negative Breast Cancer (TNBC), Brain MetastasesRecruiting
Est. primary completion 2026-12-31 · NCT06793332 · CT.gov ↗
What to watch
2027 (61)
January 2027 (7)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01 · NCT07208773 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-01 · NCT06196697 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-01 · NCT06601335 · CT.gov ↗
What to watch
Phase 3Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-01-13 · NCT06951503 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell Carcinoma, Ivonescimab, NeoadjuvantRecruiting
Est. primary completion 2027-01-28 · NCT07385001 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-01-30 · NCT07070479 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsNot yet recruiting
Est. primary completion 2027-01-31 · NCT07650825 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1/2Colorectal Cancer With Hepatic MetastasesNot yet recruiting
Est. primary completion 2027-02-28 · NCT07357220 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Rectal Cancer, Radiation, AK112Recruiting
Est. primary completion 2027-03-31 · NCT07162714 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Endometrial Cancer, Cervical CancerRecruiting
Est. primary completion 2027-04 · NCT06925724 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04-30 · NCT06936644 · CT.gov ↗
What to watch
May 2027 (7)
Phase 1/2Biliary Tract CancerRecruiting
Est. primary completion 2027-05 · NCT06938321 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-05 · NCT07009925 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT06928389 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-05-10 · NCT07052253 · CT.gov ↗
What to watch
Phase 2Cutaneous AngiosarcomaRecruiting
Est. primary completion 2027-05-11 · NCT07655570 · CT.gov ↗
What to watch
Phase 3Pancreatic CancerRecruiting
Est. primary completion 2027-05-14 · NCT06953999 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT07590531 · CT.gov ↗
What to watch
June 2027 (5)
Phase 1Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2027-06 · NCT06990620 · CT.gov ↗
What to watch
Phase 2Colorectal Liver MetastasesRecruiting
Est. primary completion 2027-06 · NCT06848842 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell CarcinomaEnrolling by invitation
Est. primary completion 2027-06-01 · NCT07488572 · CT.gov ↗
What to watch
Phase 2Thymus CarcinomaRecruiting
Est. primary completion 2027-06-17 · NCT06980077 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-30 · NCT07188103 · CT.gov ↗
What to watch
July 2027 (6)
Phase 2LOCALLY ADVANCED CERVICAL CANCERSNot yet recruiting
Est. primary completion 2027-07-01 · NCT07244965 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-01 · NCT07630077 · CT.gov ↗
What to watch
Phase 2Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic CarcinomaRecruiting
Est. primary completion 2027-07-01 · NCT06805617 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-07-10 · NCT06791148 · CT.gov ↗
What to watch
Phase 2Neoadjuvant Therapy of Operable Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-07-15 · NCT06537011 · CT.gov ↗
What to watch
Phase 1Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2027-07-21 · NCT07363408 · CT.gov ↗
What to watch
August 2027 (5)
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-08 · NCT07114315 · CT.gov ↗
What to watch
Phase 2Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-08-01 · NCT07094685 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2027-08-03 · NCT06529718 · CT.gov ↗
What to watch
Phase 2Colon CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT06790212 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-30 · NCT07669779 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Advanced Gastric AdenocarcinomaRecruiting
Est. primary completion 2027-09 · NCT06846346 · CT.gov ↗
What to watch
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2027-09-01 · NCT07591090 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-30 · NCT07339839 · CT.gov ↗
What to watch
Phase 2Metastatic Endocrine Refractory, Triple Negative Invasive Lobular CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT07229417 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Platinum-sensitive Ovarian CancerRecruiting
Est. primary completion 2027-10 · NCT06686030 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07204548 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2027-10-31 · NCT07021950 · CT.gov ↗
What to watch
November 2027 (2)
Phase 2Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular Epithelioid Cell Tumor …Recruiting
Est. primary completion 2027-11-30 · NCT06683846 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT07241819 · CT.gov ↗
What to watch
December 2027 (18)
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2027-12 · NCT07245446 · CT.gov ↗
What to watch
Phase 2TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07017673 · CT.gov ↗
What to watch
Phase 2Extensive Stage Lung Small Cell CancerRecruiting
Est. primary completion 2027-12 · NCT07057791 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT06684873 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2027-12-20 · NCT06760520 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07603791 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-30 · NCT07647016 · CT.gov ↗
What to watch
Phase 1Melanoma, Mucosal Melanoma, Metastatic MelanomaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT06424626 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07899086 · CT.gov ↗
What to watch
Phase 2Breast Cancer - FemaleNot yet recruiting
Est. primary completion 2027-12-31 · NCT07103447 · CT.gov ↗
What to watch
Phase 2Gastric Cancer, RCTNot yet recruiting
Est. primary completion 2027-12-31 · NCT07374250 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07489703 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-12-31 · NCT07244978 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07650838 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07742956 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07809893 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12-31 · NCT07472478 · CT.gov ↗
What to watch
2028 (41)
January 2028 (4)
Phase 2Pretreated Pleural MesotheliomaRecruiting
Est. primary completion 2028-01 · NCT06875076 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT07669051 · CT.gov ↗
What to watch
Phase 2Ivonescimab, Clear Cell Renal CarcinomaRecruiting
Est. primary completion 2028-01-19 · NCT06940518 · CT.gov ↗
What to watch
Phase 1/2GlioblastomaRecruiting
Est. primary completion 2028-01-31 · NCT06672575 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2028-02-18 · NCT06844422 · CT.gov ↗
What to watch
Phase 1Pancreas Cancer, Pancreas Cancer, Duct Cell AdenocarcinomaNot yet recruiting
Est. primary completion 2028-02-23 · NCT06913218 · CT.gov ↗
What to watch
March 2028 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-01 · NCT07405190 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant TumorsRecruiting
Est. primary completion 2028-03-30 · NCT06877650 · CT.gov ↗
What to watch
Phase 2Metastatic Breast Cancer ( HER2 Negative), ctDNARecruiting
Est. primary completion 2028-03-31 · NCT07394218 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-31 · NCT07412262 · CT.gov ↗
What to watch
April 2028 (4)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07535463 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07535437 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT06767514 · CT.gov ↗
What to watch
Phase 2Gastric (Cardia, Body) CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT06904300 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Adrenocortical Carcinoma, Pheochromocytoma, ParagangliomaNot yet recruiting
Est. primary completion 2028-05-01 · NCT07743138 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05-12 · NCT07594522 · CT.gov ↗
What to watch
Phase 3Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-05-31 · NCT07228832 · CT.gov ↗
What to watch
June 2028 (5)
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2028-06-06 · NCT07560124 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-18 · NCT07623356 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06868732 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2028-06-30 · NCT06929663 · CT.gov ↗
What to watch
Phase 2Gallbladder CancerNot yet recruiting
Est. primary completion 2028-06-30 · NCT07767994 · CT.gov ↗
What to watch
July 2028 (5)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-07 · NCT07614646 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07 · NCT07158489 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07-01 · NCT06951646 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2028-07-01 · NCT06959550 · CT.gov ↗
What to watch
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Urothelial Carcinoma (UC)Not yet recruiting
Est. primary completion 2028-08-24 · NCT07636772 · CT.gov ↗
What to watch
Phase 2Cervical CancersRecruiting
Est. primary completion 2028-08-31 · NCT07130240 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-09 · NCT07158840 · CT.gov ↗
What to watch
Phase 2Cutaneous Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT06567314 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-10 · NCT07854600 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07936578 · CT.gov ↗
What to watch
November 2028 (2)
Phase 1/2Malignant Pleural Mesothelioma, AdvancedRecruiting
Est. primary completion 2028-11-30 · NCT07885319 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT07393555 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2SCLC, RecurrentNot yet recruiting
Est. primary completion 2028-12-01 · NCT07819591 · CT.gov ↗
What to watch
Phase 2Localized Clear Cell Renal Cell Carcinoma, Resectable Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 …Recruiting
Est. primary completion 2028-12-05 · NCT07226544 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12-31 · NCT07381075 · CT.gov ↗
What to watch
Phase 2/3Biliary Tract CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07765433 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07010263 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-12-31 · NCT05899608 · CT.gov ↗
What to watch
2029 (11)
January 2029 (1)
Phase 2TNBC, Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2029-01 · NCT06977542 · CT.gov ↗
What to watch
February 2029 (2)
Phase 2Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCCNot yet recruiting
Est. primary completion 2029-02-10 · NCT06814067 · CT.gov ↗
What to watch
Phase 2Neuroendocrine CancerNot yet recruiting
Est. primary completion 2029-02-27 · NCT07712094 · CT.gov ↗
What to watch
March 2029 (1)
Phase 1Clear Cell Renal Cell Carcinoma, Solid TumorsRecruiting
Est. primary completion 2029-03 · NCT05536141 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2LeiomyosarcomaRecruiting
Est. primary completion 2029-04 · NCT07516925 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma, Clear CellNot yet recruiting
Est. primary completion 2029-04-12 · NCT07877194 · CT.gov ↗
What to watch
May 2029 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05 · NCT07619339 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05 · NCT07397338 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-06 · NCT07917481 · CT.gov ↗
What to watch
Phase 1/2Neoplasms, LungRecruiting
Est. primary completion 2029-06-22 · NCT07602855 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2029-08 · NCT07359456 · CT.gov ↗
What to watch
2030 (4)
May 2030 (1)
Phase 3Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)Recruiting
Est. primary completion 2030-05 · NCT07264075 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT07941583 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2/3Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)Recruiting
Est. primary completion 2030-10-31 · NCT07815665 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (2)
May 2031 (1)
Phase 2Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2031-05 · NCT07565389 · CT.gov ↗
What to watch
November 2031 (1)
Phase 2Phase II, Ivonescimab, Intraperitoneal, Paclitaxel, High Grade Metastatic, Appendiceal AdenocarcinomaNot yet recruiting
Est. primary completion 2031-11-28 · NCT07753824 · CT.gov ↗
What to watch
2032 (2)
January 2032 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2032-01 · NCT07234877 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Breast Cancer, Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2032-12 · NCT07743632 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 November 2026FDA action dateIvonescimab PDUFA goal action date (EGFRm NSCLC post-TKI)
US, FDA · FDA · Source ↗
5 November 2026Priority reviewNMPA grants priority review to ivonescimab plus chemotherapy in first-line biliary tract cancer
CN, NMPA · Akeso · Source ↗
25 October 2026Topline resultPhase 3 HARMONi-GI1 met its primary endpoint of overall survival
12 August 2026ApprovalNMPA approves ivonescimab plus chemotherapy in first-line squamous NSCLC
CN, NMPA · Source ↗
29 January 2026Filing acceptedFDA accepts Summit's BLA for ivonescimab plus chemotherapy (EGFRm NSCLC post-TKI)
US, FDA · FDA · Source ↗